Attempt Suicide Clinical Trial
Official title:
Genetic Variants Associated With Adolescent Suicide Attempts: a Candidate-gene Association Study.
Suicidal behaviors is known to aggregate in families. The purpose of this study is to evaluate association between common polymorphisms in genes important for neurobiological pathways linked to suicidal behaviors and suicide attempt among adolescents patient.
In France, suicide is the second leading cause of death among the 14-22 years population.
Suicide behavior (SB) spans a spectrum ranging from suicidal ideation to suicide attempts
and completed suicide. Several factors likely determine the predisposition to SB, including
biological factors and psychosocial stressors. For biological factors, convergent evidence
from adoption, family, and twin studies of suicide strongly suggests genetic contributions
to liability for SB. Although genetic factors play a role in SB, identifying specific genes
involved has proved challenging. Molecular-genetic technologies have made great advances in
the past decade, including genome- wide searches for disease-causing genes with the linkage
disequilibrium (LD) approach. Despite being a major public health problem in the youth
population, genetic associations studies regarding suicidal behavior in adolescence are
still rare. Genes that code for proteins involved in regulating serotonergic
neurotransmission have thus been major candidate genes for association studies of SB. Among
them, genes for serotonin metabolism (tryptophan hydroxylase, TPH), serotonin transport
(5-HTT), and the serotonergic 2A (5-HT2A) receptor have received the most research
attention.
The identification of relevant genetic variants or SNPs in others genes which are involved
in the neurobiological pathways (which the alteration may contribute to a suicidal behavior)
can help not only to advance knowledge of the genetic bases of suicide but also to identify
new therapeutic targets.
On the basis of review of the literature, investigators will identify candidate genes that
have been reported to be associated with suicidal events.
The investigators will target genes related to central serotonergic and noradrenergic
neurotransmission, and monoamine metabolism (MAOA). The investigators will also study genes
involved in glutamatergic neurotransmission (GRIK2, GRIA3) and in the HPA axis (FKBP5) and
genes that code for neurotrophic proteins (BDNF).
DNA will be obtained from saliva. All genotyping will be carried out using standard
polymerase chain reaction-based techniques that are routinely used in the Human Genetics
Laboratory. DNA segments containing the target variable site will be amplified using unique
sequence flanking primers.
Tests of association between genetic variant and suicide attempt will be conducted using Chi
squared and Armitage Trend Tests. Logistical regression analyses will be performed to
evaluate the contribution of individual genetic variant to the prediction of suicide
attempt, and to examine SNPs for potential gene-gene and gene-environment interactions.
;
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04905797 -
Aspects of Self-harm - Cognition, Imaging and Treatability
|